leadf
logo-loader
viewOncimmune

Oncimmune Hldngs PLC - Draw down of second tranche of credit facility

RNS Number : 0611S
Oncimmune Holdings PLC
04 November 2019
 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Draw down of second 3.5 million tranche of credit facility

 

4 November 2019 - Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, today announces it has drawn down the second tranche of its previously announced credit facility of €8.5 million with IPF Management SA ("IPF") (the "Facility"). 

 

Oncimmune drew down an initial €5.0 million on completion in 20 September 2019. The second tranche of €3.5 million was drawn down on 18 October 2019.

 

 

-Ends-

 

 

For further information:

Oncimmune Holdings plc

Matthew Hall, Chief Financial Officer

[email protected]

 

Cléa Rosenfeld, Head of Investor Relations

[email protected]  

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

+44 (0)20 3829 5000

 

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

+44 (0)20 7220 0500

 

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

 

Media enquiries:

FTI Consulting

Ben Atwell, Brett Pollard, Andrew Ward

[email protected] 

+44 (0)20 3727 1000

 

 

About Oncimmune

Beating cancer, one test at a time

 

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

 

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

 

What is EarlyCDT Lung?

 

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

 

 

For more information, visit www.oncimmune.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBLBDBCXGBGCX

Quick facts: Oncimmune

Price: 147.5

Market: AIM
Market Cap: £93.72 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20